Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Anti-HIV Agents | 16 | 2021 | 2209 | 1.50 | Why? |
| HIV Infections | 32 | 2021 | 11620 | 1.50 | Why? |
| AIDS-Related Opportunistic Infections | 2 | 2021 | 260 | 1.34 | Why? |
| Uganda | 22 | 2019 | 1057 | 1.01 | Why? |
| Malaria, Falciparum | 7 | 2019 | 377 | 0.99 | Why? |
| Artemisinins | 7 | 2019 | 238 | 0.89 | Why? |
| Heterocyclic Compounds, 3-Ring | 2 | 2019 | 275 | 0.77 | Why? |
| Anti-Retroviral Agents | 3 | 2018 | 1099 | 0.77 | Why? |
| Quinolines | 6 | 2019 | 403 | 0.70 | Why? |
| Tuberculosis | 5 | 2021 | 2895 | 0.69 | Why? |
| Rural Population | 10 | 2019 | 2408 | 0.68 | Why? |
| Antimalarials | 9 | 2019 | 2505 | 0.61 | Why? |
| HIV Seropositivity | 2 | 2017 | 320 | 0.60 | Why? |
| HIV | 2 | 2019 | 1116 | 0.57 | Why? |
| Pregnancy Complications, Parasitic | 3 | 2018 | 23 | 0.56 | Why? |
| Skilled Nursing Facilities | 2 | 2020 | 1098 | 0.55 | Why? |
| San Francisco | 6 | 2022 | 711 | 0.54 | Why? |
| Kenya | 9 | 2019 | 887 | 0.53 | Why? |
| Homeless Persons | 2 | 2021 | 1171 | 0.42 | Why? |
| Community Health Services | 4 | 2019 | 1000 | 0.41 | Why? |
| Congresses as Topic | 1 | 2018 | 1347 | 0.36 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.34 | Why? |
| Sustained Virologic Response | 2 | 2020 | 378 | 0.33 | Why? |
| Rural Health Services | 1 | 2014 | 496 | 0.33 | Why? |
| Diagnostic Tests, Routine | 2 | 2021 | 2643 | 0.32 | Why? |
| Malaria | 4 | 2017 | 1097 | 0.32 | Why? |
| CD4 Lymphocyte Count | 4 | 2018 | 1517 | 0.31 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.30 | Why? |
| Health Care Rationing | 1 | 2020 | 2558 | 0.29 | Why? |
| Mosquito Control | 2 | 2017 | 237 | 0.29 | Why? |
| Premature Birth | 4 | 2017 | 2151 | 0.28 | Why? |
| Sulfadoxine | 3 | 2018 | 14 | 0.28 | Why? |
| Plasmodium falciparum | 2 | 2017 | 337 | 0.27 | Why? |
| Antiretroviral Therapy, Highly Active | 3 | 2014 | 952 | 0.26 | Why? |
| Pyrimethamine | 2 | 2018 | 18 | 0.24 | Why? |
| Lost to Follow-Up | 2 | 2017 | 79 | 0.22 | Why? |
| Oxazines | 2 | 2019 | 279 | 0.21 | Why? |
| Comorbidity | 3 | 2021 | 34796 | 0.21 | Why? |
| Health Promotion | 1 | 2014 | 2020 | 0.20 | Why? |
| Point-of-Care Systems | 1 | 2014 | 2955 | 0.20 | Why? |
| Pre-Exposure Prophylaxis | 2 | 2019 | 1138 | 0.20 | Why? |
| Viral Load | 5 | 2021 | 15850 | 0.20 | Why? |
| Botswana | 1 | 2019 | 98 | 0.20 | Why? |
| Emergency Shelter | 1 | 2021 | 202 | 0.20 | Why? |
| Piperazines | 2 | 2019 | 445 | 0.19 | Why? |
| Antitubercular Agents | 2 | 2019 | 775 | 0.19 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 1 | 2019 | 66 | 0.19 | Why? |
| Isoniazid | 1 | 2019 | 105 | 0.19 | Why? |
| Coinfection | 1 | 2019 | 6820 | 0.19 | Why? |
| Interrupted Time Series Analysis | 1 | 2021 | 868 | 0.17 | Why? |
| Cryptococcosis | 1 | 2018 | 97 | 0.16 | Why? |
| Alkynes | 4 | 2018 | 98 | 0.16 | Why? |
| Pyridones | 2 | 2019 | 738 | 0.16 | Why? |
| Bone Diseases | 1 | 2017 | 101 | 0.15 | Why? |
| Benzoxazines | 4 | 2018 | 103 | 0.15 | Why? |
| Insecticides | 1 | 2017 | 178 | 0.15 | Why? |
| HIV Integrase Inhibitors | 1 | 2017 | 173 | 0.15 | Why? |
| Behavior Therapy | 1 | 2018 | 235 | 0.14 | Why? |
| Drug Resistance | 1 | 2017 | 395 | 0.14 | Why? |
| Humans | 49 | 2022 | 930598 | 0.14 | Why? |
| Health Services Accessibility | 2 | 2020 | 10697 | 0.14 | Why? |
| Cyclopropanes | 4 | 2018 | 332 | 0.13 | Why? |
| Metabolic Diseases | 1 | 2019 | 505 | 0.13 | Why? |
| Adult | 29 | 2021 | 244371 | 0.12 | Why? |
| Metabolomics | 1 | 2019 | 921 | 0.12 | Why? |
| Young Adult | 17 | 2021 | 93724 | 0.12 | Why? |
| Stillbirth | 1 | 2017 | 544 | 0.12 | Why? |
| Mass Screening | 3 | 2018 | 8005 | 0.12 | Why? |
| Mycoses | 1 | 2019 | 589 | 0.12 | Why? |
| Pregnancy Complications, Infectious | 5 | 2017 | 11559 | 0.12 | Why? |
| Adolescent | 14 | 2021 | 86841 | 0.12 | Why? |
| Communicable Disease Control | 2 | 2020 | 29620 | 0.11 | Why? |
| Disease Eradication | 1 | 2018 | 581 | 0.11 | Why? |
| Poverty | 2 | 2020 | 2302 | 0.11 | Why? |
| Patient Acceptance of Health Care | 3 | 2018 | 5002 | 0.11 | Why? |
| Drug Combinations | 5 | 2018 | 3852 | 0.11 | Why? |
| Female | 32 | 2021 | 380317 | 0.11 | Why? |
| Time Factors | 5 | 2021 | 31397 | 0.11 | Why? |
| Polymorphism, Genetic | 1 | 2017 | 1074 | 0.10 | Why? |
| Health Care Costs | 1 | 2018 | 1007 | 0.10 | Why? |
| Autoantibodies | 1 | 2021 | 2094 | 0.10 | Why? |
| Pyrimidinones | 1 | 2009 | 76 | 0.10 | Why? |
| ADP-ribosyl Cyclase 1 | 1 | 2009 | 96 | 0.10 | Why? |
| Pregnancy | 11 | 2018 | 23879 | 0.10 | Why? |
| Ethanolamines | 1 | 2009 | 71 | 0.09 | Why? |
| Carrier State | 1 | 2021 | 2100 | 0.09 | Why? |
| Cluster Analysis | 1 | 2017 | 3001 | 0.09 | Why? |
| Fluorenes | 1 | 2009 | 101 | 0.09 | Why? |
| Parasitemia | 2 | 2019 | 88 | 0.09 | Why? |
| Delivery of Health Care | 3 | 2020 | 15909 | 0.09 | Why? |
| Male | 24 | 2021 | 367725 | 0.09 | Why? |
| Interferon Type I | 1 | 2021 | 2789 | 0.09 | Why? |
| Incidence | 6 | 2022 | 25622 | 0.09 | Why? |
| Public Policy | 1 | 2020 | 1894 | 0.09 | Why? |
| Point-of-Care Testing | 1 | 2021 | 2782 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.09 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.09 | Why? |
| Motivation | 1 | 2018 | 1640 | 0.09 | Why? |
| Insecticide-Treated Bednets | 2 | 2017 | 77 | 0.08 | Why? |
| Delivery of Health Care, Integrated | 1 | 2019 | 1549 | 0.08 | Why? |
| Double-Blind Method | 4 | 2019 | 5988 | 0.08 | Why? |
| Placenta | 1 | 2017 | 1531 | 0.08 | Why? |
| HLA-DR Antigens | 1 | 2009 | 563 | 0.08 | Why? |
| Tuberculosis, Pulmonary | 2 | 2019 | 1171 | 0.07 | Why? |
| HIV Protease Inhibitors | 1 | 2009 | 434 | 0.07 | Why? |
| Primary Health Care | 2 | 2021 | 4839 | 0.07 | Why? |
| Ritonavir | 4 | 2017 | 4212 | 0.07 | Why? |
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2017 | 170 | 0.07 | Why? |
| Pregnancy Complications | 1 | 2016 | 1388 | 0.07 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.07 | Why? |
| Child, Preschool | 6 | 2020 | 36283 | 0.07 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.07 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.06 | Why? |
| Infant, Newborn | 7 | 2018 | 23105 | 0.06 | Why? |
| Middle Aged | 15 | 2021 | 270681 | 0.06 | Why? |
| Phylogeny | 1 | 2021 | 13341 | 0.06 | Why? |
| Chemoprevention | 2 | 2017 | 585 | 0.06 | Why? |
| Models, Theoretical | 1 | 2020 | 6659 | 0.06 | Why? |
| Drug Administration Schedule | 2 | 2018 | 2324 | 0.06 | Why? |
| Treatment Outcome | 8 | 2018 | 51732 | 0.05 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2018 | 5164 | 0.05 | Why? |
| Public Health | 3 | 2021 | 16359 | 0.05 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.05 | Why? |
| Drug Therapy, Combination | 3 | 2019 | 7268 | 0.05 | Why? |
| No-Show Patients | 1 | 2020 | 94 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Lopinavir | 4 | 2017 | 4308 | 0.05 | Why? |
| HIV Antibodies | 1 | 2005 | 776 | 0.05 | Why? |
| Child | 6 | 2020 | 70012 | 0.05 | Why? |
| Lymphocyte Activation | 1 | 2009 | 2742 | 0.05 | Why? |
| Trimethoprim | 1 | 2017 | 22 | 0.05 | Why? |
| Endoglin | 1 | 2017 | 16 | 0.05 | Why? |
| Angiopoietin-1 | 1 | 2017 | 25 | 0.04 | Why? |
| Safety-net Providers | 1 | 2020 | 302 | 0.04 | Why? |
| Epidemics | 1 | 2018 | 6407 | 0.04 | Why? |
| Placenta Growth Factor | 1 | 2017 | 93 | 0.04 | Why? |
| Hypertension | 1 | 2019 | 8895 | 0.04 | Why? |
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2017 | 120 | 0.04 | Why? |
| Infant, Small for Gestational Age | 1 | 2017 | 151 | 0.04 | Why? |
| Employment | 2 | 2018 | 1754 | 0.04 | Why? |
| Angiopoietin-2 | 1 | 2017 | 125 | 0.04 | Why? |
| Aircraft | 1 | 2021 | 498 | 0.04 | Why? |
| Neovascularization, Physiologic | 1 | 2017 | 160 | 0.04 | Why? |
| Infant, Low Birth Weight | 1 | 2017 | 243 | 0.04 | Why? |
| Pregnancy Trimester, Second | 1 | 2017 | 314 | 0.04 | Why? |
| Infant | 4 | 2019 | 30274 | 0.04 | Why? |
| Pregnancy Trimester, Third | 1 | 2017 | 445 | 0.04 | Why? |
| Chromatography, Liquid | 1 | 2019 | 640 | 0.04 | Why? |
| Endpoint Determination | 1 | 2017 | 344 | 0.04 | Why? |
| Community Health Workers | 1 | 2020 | 468 | 0.04 | Why? |
| Social Support | 2 | 2020 | 3183 | 0.04 | Why? |
| Models, Economic | 1 | 2017 | 316 | 0.03 | Why? |
| Risk Factors | 4 | 2018 | 71621 | 0.03 | Why? |
| Transgender Persons | 1 | 2018 | 322 | 0.03 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2009 | 4545 | 0.03 | Why? |
| Disclosure | 1 | 2018 | 423 | 0.03 | Why? |
| Costs and Cost Analysis | 1 | 2018 | 694 | 0.03 | Why? |
| United States | 1 | 2021 | 46150 | 0.03 | Why? |
| RNA, Viral | 2 | 2021 | 32276 | 0.03 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2017 | 604 | 0.03 | Why? |
| Withholding Treatment | 1 | 2019 | 798 | 0.03 | Why? |
| Tandem Mass Spectrometry | 1 | 2019 | 1031 | 0.03 | Why? |
| Aged | 6 | 2020 | 215776 | 0.03 | Why? |
| Africa South of the Sahara | 1 | 2017 | 1335 | 0.03 | Why? |
| Anemia | 1 | 2019 | 789 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2017 | 11497 | 0.03 | Why? |
| Asymptomatic Infections | 2 | 2021 | 7218 | 0.03 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2009 | 5837 | 0.03 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2018 | 533 | 0.03 | Why? |
| Sex Characteristics | 1 | 2019 | 1120 | 0.03 | Why? |
| Interviews as Topic | 1 | 2020 | 1952 | 0.03 | Why? |
| Reagent Kits, Diagnostic | 1 | 2021 | 2149 | 0.03 | Why? |
| HIV-1 | 1 | 2005 | 3365 | 0.03 | Why? |
| Neoplasms | 1 | 2019 | 17251 | 0.03 | Why? |
| Program Evaluation | 1 | 2018 | 1929 | 0.03 | Why? |
| Genomics | 1 | 2022 | 3118 | 0.02 | Why? |
| Cytochrome P-450 CYP3A | 1 | 2009 | 88 | 0.02 | Why? |
| Social Stigma | 1 | 2018 | 1049 | 0.02 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.02 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.02 | Why? |
| Homosexuality, Male | 1 | 2018 | 1158 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Sexual and Gender Minorities | 1 | 2018 | 1019 | 0.02 | Why? |
| Fatigue | 1 | 2018 | 2479 | 0.02 | Why? |
| Africa | 1 | 2016 | 2986 | 0.02 | Why? |
| Pilot Projects | 1 | 2019 | 5182 | 0.02 | Why? |
| Qualitative Research | 1 | 2018 | 4337 | 0.02 | Why? |
| Computer Simulation | 1 | 2021 | 4982 | 0.02 | Why? |
| African Americans | 1 | 2020 | 3363 | 0.02 | Why? |
| Pregnancy Outcome | 1 | 2018 | 3803 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2018 | 3129 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2018 | 3493 | 0.02 | Why? |
| Chronic Disease | 1 | 2019 | 5139 | 0.02 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.02 | Why? |
| T-Lymphocyte Subsets | 1 | 2011 | 1387 | 0.02 | Why? |
| Fear | 1 | 2018 | 3607 | 0.02 | Why? |
| Travel | 1 | 2021 | 7220 | 0.01 | Why? |
| Area Under Curve | 1 | 2009 | 2564 | 0.01 | Why? |
| Drug Interactions | 1 | 2009 | 1653 | 0.01 | Why? |
| Models, Biological | 1 | 2018 | 4907 | 0.01 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2019 | 53120 | 0.01 | Why? |
| Health Policy | 1 | 2017 | 6242 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Risk Assessment | 1 | 2019 | 25439 | 0.01 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.01 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2019 | 88759 | 0.01 | Why? |
| Cytokines | 1 | 2011 | 15010 | 0.01 | Why? |
| Animals | 1 | 2016 | 78931 | 0.01 | Why? |
Havlir's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(215)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(146)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_